These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 26744739)

  • 21. Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders.
    Abbas A; Roth BL
    Expert Opin Pharmacother; 2008 Dec; 9(18):3251-9. PubMed ID: 19040345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pimavanserin as treatment for Parkinson's disease psychosis.
    Fox SH
    Lancet; 2014 Feb; 383(9916):494-6. PubMed ID: 24183566
    [No Abstract]   [Full Text] [Related]  

  • 23. The US Food and Drug Administration's Perspective on the New Antipsychotic Pimavanserin.
    Mathis MV; Muoio BM; Andreason P; Avila AM; Farchione T; Atrakchi A; Temple RJ
    J Clin Psychiatry; 2017 Jun; 78(6):e668-e673. PubMed ID: 28493654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blinded SAPS-PD Assessment After 10 Weeks of Pimavanserin Treatment for Parkinson's Disease Psychosis.
    Isaacson SH; Coate B; Norton J; Stankovic S
    J Parkinsons Dis; 2020; 10(4):1389-1396. PubMed ID: 32716320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nighttime Sleep and Daytime Sleepiness Improved With Pimavanserin During Treatment of Parkinson's Disease Psychosis.
    Patel N; LeWitt P; Neikrug AB; Kesslak P; Coate B; Ancoli-Israel S
    Clin Neuropharmacol; 2018; 41(6):210-215. PubMed ID: 30303817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Parkinson's Disease Psychosis and the Marketing of Pimavanserin.
    Daeschler D; Fugh-Berman A
    Int J Soc Determinants Health Health Serv; 2024 Jul; 54(3):272-284. PubMed ID: 38592164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist.
    Nasrallah HA; Fedora R; Morton R
    Schizophr Res; 2019 Jun; 208():217-220. PubMed ID: 30837203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serotonin 2A Receptor Inverse Agonist as a Treatment for Parkinson's Disease Psychosis: A Systematic Review and Meta-analysis of Serotonin 2A Receptor Negative Modulators.
    Yasue I; Matsunaga S; Kishi T; Fujita K; Iwata N
    J Alzheimers Dis; 2016; 50(3):733-40. PubMed ID: 26757194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pimavanserin: a new treatment for the Parkinson's disease psychosis].
    Duits JH; Ongering MS; Martens HJM; Schulte PFJ
    Tijdschr Psychiatr; 2017; 59(9):528-536. PubMed ID: 28880354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Perspective on Pimavanserin and the SAPS-PD: Novel Scale Development as a Means to FDA Approval.
    Schubmehl S; Sussman J
    Am J Geriatr Psychiatry; 2018 Oct; 26(10):1007-1011. PubMed ID: 30072306
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease.
    Price DL; Bonhaus DW; McFarland K
    Behav Pharmacol; 2012 Aug; 23(4):426-33. PubMed ID: 22750845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.
    Ballard C; Banister C; Khan Z; Cummings J; Demos G; Coate B; Youakim JM; Owen R; Stankovic S;
    Lancet Neurol; 2018 Mar; 17(3):213-222. PubMed ID: 29452684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trial of Pimavanserin in Dementia-Related Psychosis.
    Tariot PN; Cummings JL; Soto-Martin ME; Ballard C; Erten-Lyons D; Sultzer DL; Devanand DP; Weintraub D; McEvoy B; Youakim JM; Stankovic S; Foff EP
    N Engl J Med; 2021 Jul; 385(4):309-319. PubMed ID: 34289275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus.
    Black KJ; Nasrallah H; Isaacson S; Stacy M; Pahwa R; Adler CH; Alva G; Cooney JW; Kremens D; Menza MA; Meyer JM; Patkar AA; Simuni T; Morrissette DA; Stahl SM
    CNS Spectr; 2018 Dec; 23(6):402-413. PubMed ID: 30588905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dementia-related psychosis and the potential role for pimavanserin.
    Cummings JL; Devanand DP; Stahl SM
    CNS Spectr; 2022 Feb; 27(1):7-15. PubMed ID: 32811586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pimavanserin in Alzheimer's Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms.
    Ballard C; Youakim JM; Coate B; Stankovic S
    J Prev Alzheimers Dis; 2019; 6(1):27-33. PubMed ID: 30569083
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients.
    Isaacson SH; Ballard CG; Kreitzman DL; Coate B; Norton JC; Fernandez HH; Ilic TV; Azulay JP; Ferreira JJ; Abler V; Stankovic S;
    Parkinsonism Relat Disord; 2021 Jun; 87():25-31. PubMed ID: 33933853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Behavioral effects of clozapine, pimavanserin, and quetiapine in rodent models of Parkinson's disease and Parkinson's disease psychosis: evaluation of therapeutic ratios.
    Hubbard D; Hacksell U; McFarland K
    Behav Pharmacol; 2013 Oct; 24(7):628-32. PubMed ID: 23969614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pimavanserin, a 5HT
    Yuede CM; Wallace CE; Davis TA; Gardiner WD; Hettinger JC; Edwards HM; Hendrix RD; Doherty BM; Yuede KM; Burstein ES; Cirrito JR
    J Neurochem; 2021 Mar; 156(5):658-673. PubMed ID: 33278025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. On the Optimal Diagnosis and the Evolving Role of Pimavanserin in Parkinson's Disease Psychosis.
    Pagan FL; Schulz PE; Torres-Yaghi Y; Pontone GM
    CNS Drugs; 2024 May; 38(5):333-347. PubMed ID: 38587586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.